Clinical Trials Logo

Urinary Bladder, Neurogenic clinical trials

View clinical trials related to Urinary Bladder, Neurogenic.

Filter by:

NCT ID: NCT01389921 Completed - Healthy Clinical Trials

Study of Electroencephalogram (EEG) Measurement During Different Stimulations of the Lower Urinary Tract

Start date: February 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate afferent and cortical activities during bladder filling under different stimulations of the lower urinary tract. The participants of the study are healthy test persons and patients with overactive bladder.

NCT ID: NCT01388413 Completed - Clinical trials for Urinary Tract Infection

Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder

PACHIU
Start date: August 2011
Phase: Phase 4
Study type: Interventional

Symptomatic urinary tract infections (UTIs) are one of the main causes of morbidity and the main cause of re-hospitalization in subjects with neurogenic bladder. Long-term antibiotic therapy increases the risk of multi-resistant bacterial infections, without reducing the rate of symptomatic UTIs. Our non-comparative preliminary study has shown that Weekly Oral Cyclic Antibiotic Programme (single, weekly dose of antibiotic X on even weeks, and antibiotic Y on odd weeks) seem to drastically reduce both the number of symptomatic UTIs and the number of hospitalizations in patients with neurogenic bladder, without affecting bacterial ecology. The objective of this study is to validate this preliminary work with a large-scale randomized, parallel-group, multicenter study.

NCT ID: NCT01337024 Completed - Clinical trials for Bladder Disorder, Neurogenic

Heart Rate Variability (HRV) in Patients With Neurogenic Detrusor Overactivity (NDO) Before and After Botulinum Neurotoxin Type A (BoNT/A) Intradetrusor Injections

HRV/Botox
Start date: March 2010
Phase: N/A
Study type: Observational

Heart rate variability (HRV) is an important indicator of cardiac autonomic function and predictor of cardiac mortality and of all-cause mortality. In this study the investigators examined changes of the HRV in patients with neurogenic detrusor overactivity (NDO) undergoing botulinum neurotoxin type A intradetrusor injections (BoNT/A).

NCT ID: NCT01305681 Withdrawn - Urinary Retention Clinical Trials

Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization

Start date: May 6, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of our study is to examine characteristics of bacteria that are discovered in urine from pediatric patients that utilize either LoFric® or non-LoFric® catheters for self intermittent catheterization. The investigators hypothesize that the hydrophilic nature of the LoFric® catheter will alter the microbial environment and reduce clinically significant urinary tract infections in patients with neurogenic bladder compared to a similar population using standard catheters. Secondary outcomes will be comparing the incidence of clinical urinary tract infections between patients that use standard catheters and those that use LoFric catheters. Lastly, patient satisfaction using LoFric catheters compared to standard catheters will be assessed.

NCT ID: NCT01299792 Completed - Spinal Cord Injury Clinical Trials

Sonographic Measurement of Bladder Wall Thickness in Patients With Neurogenic Bladder Dysfunction

Start date: August 2009
Phase:
Study type: Observational

Video-urodynamic investigations are regarded as the current standard diagnostics for neurogenic bladder dysfunction in patients with spinal cord injury. This examination is exact, but time consuming, costly and associated with the risk of urinary tract infection. In patients with lower urinary tract symptoms due to benign prostate hyperplasia, sonographic measurement of bladder wall thickness has been demonstrated to be able to replace urodynamic testing for the diagnosis of infravesical obstruction. Hypothesis: measurement of bladder wall thickness in patients with neurogenic bladder dysfunction due to spinal cord injury is closely related to the known risk factors for upper urinary tract deterioration (bladder compliance, detrusor leak point pressure) in this group of patients and can therefore replace urodynamic examination in selected cases.

NCT ID: NCT01297660 Completed - Clinical trials for Urinary Bladder Neurogenic Dysfunction

Neuro-urological Outcome After Spinal Cord Injury

Start date: January 2010
Phase: N/A
Study type: Observational

Most patients with spinal cord injury suffer from bladder dysfunction which may - especially in the long-term - impair renal function. Improved treatment during the last decades improved life expectancy and quality of life. This study evaluates the bladder function in the long-term after spinal cord injury.

NCT ID: NCT01297647 Completed - Neurogenic Bladder Clinical Trials

Incidence of Urinary Tract Infection After Urodynamic Investigation

Start date: May 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the incidence of urinary tract infection after urodynamic investigation and to identify the involved germs.

NCT ID: NCT01293110 Recruiting - Neurogenic Bladder Clinical Trials

Lower Urinary Tract Dysfunction Database

Start date: January 2010
Phase:
Study type: Observational

Patients with neurological disease/injury often suffer from lower urinary tract symptoms, which frequently have a negative impact on the patients' health related quality of life. The prevalence of lower urinary tract dysfunction is high and the treatment is a challenge because available treatments may fail. In this study data of patients with lower urinary tract dysfunction treated at the University of Zürich, are prospectively and systematically collected in a database.

NCT ID: NCT01263392 Completed - Neurogenic Bladder Clinical Trials

Comparing Urinary Tract Infections in Children With Spina Bifida Using Two Types of Catheters for Catheterization

Start date: April 2007
Phase: N/A
Study type: Interventional

The primary aim of this study was to determine if using the SpeediCath hydrophilic catheter would reduce the incidence of symptomatic urinary tract infections (UTI)in children with spina bifida who perform clean intermittent catheterization for bladder management. The hypothesis was that the incidence of symptomatic urinary tract infections would be significantly reduced (by 25%) in users of the SpeediCath hydrophilic catheter when compared to users of a reused polyvinyl chloride (PVC) catheter. Subjects were randomly assigned to either starting the study with PVC catheter for 6 months followed by the hydrophilic catheter for 6 months or visa versa. Each subject kept a weekly diary recording urinary tract infections symptoms, hematuria determined by urine dipstick, physician visits, days of missed school and other activities. At the end of each 6 months subjects completed a questionnaire recording their comfort and satisfaction in using the PVC or hydrophilic coated catheter. 70 subjects were randomized and 46 had complete data. There were no differences in febrile UTI, antibiotic use, healthcare visits or school days missed. The incidence of self reported UTI was lower in the PVC group than the hydrophilic group. 40% of subjects indicated that the hydrophilic coated catheter was slippery and difficult to handle compared to 10% for the PVC catheter. However overall satisfaction was no different between products. The study results are consistent with the current Cochrane Review that there is a lack of evidence to state that the incidence of UTI is affected by multiuse or hydrophilic catheter use.

NCT ID: NCT01228370 Completed - Neurogenic Bladder Clinical Trials

Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder

Start date: April 2011
Phase: Phase 4
Study type: Interventional

Because the bladder neck and proximal urethra contain abundant α1-adrenergic receptors, α-blockers or α1-blockers are well-known to reduce bladder neck obstruction in patients with or without neurogenic bladder. α1-blockers seem to have a potential to reduce bladder outlet resistance during voiding in patients with neurogenic bladder. Based on these turnouts, we designed this clinical study to evaluate the clinical effect and safety of silodosin on voiding dysfunction associated with neurogenic bladder.